74 related articles for article (PubMed ID: 227425)
1. Studies on the mechanism of action of protacine (CR 604), a new non-steroidal anti-inflammatory agent.
Vidal y Plana RR; Makovec F; Cifarelli A; Bizzarri D; Setnikar I; Rovati AL
Arzneimittelforschung; 1979; 29(8):1122-5. PubMed ID: 227425
[TBL] [Abstract][Full Text] [Related]
2. Studies on the safety of a new non-steroidal anti-inflammatory drug: protacine (CR 604).
Vidal y Plana RR; Cifarelli A; Bizzarri D; Senin P; Makovec F
Arzneimittelforschung; 1979; 29(8):1126-9. PubMed ID: 583009
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological study of a new non-steroidal anti-inflammatory drug: protacine (CR 604).
Rovati AL; Vidal y Plana RR; Casula PL; Bizzarri D; Makovec F; Setnikar I
Arzneimittelforschung; 1979; 29(8):1116-22. PubMed ID: 315235
[TBL] [Abstract][Full Text] [Related]
4. [On the pharmacodynamics of acemetacin (author's transl)].
Jacobi H; Dell HD
Arzneimittelforschung; 1980; 30(8A):1348-62. PubMed ID: 6968219
[TBL] [Abstract][Full Text] [Related]
5. [Action of nonsteroidal anti-inflammatory agents on fibrinolysis and platelet aggregation].
Lakin KM; Schipilowa SJ; Nowikowa NW; Rukasenkow JE; Pomojnezkij WD; Grenadjorow SJ
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):230-5. PubMed ID: 2427406
[TBL] [Abstract][Full Text] [Related]
6. The action of non-steroidal antiinflammatory agents on platelet aggregation and vessel tone in relation to inhibition of PGI2- and thromboxane-release. With particular reference to 5-benzoyl-alpha-methyl-2-thiophene acetic acid (tiaprofenic acid).
Kuhn A; Sauerland S; Schiffer K; Schrör K
Arzneimittelforschung; 1980; 30(9):1538-42. PubMed ID: 7006618
[TBL] [Abstract][Full Text] [Related]
7. Trifenagrel: a chemically novel platelet aggregation inhibitor.
Abrahams SL; Hazen RJ; Batson AG; Phillips AP
J Pharmacol Exp Ther; 1989 May; 249(2):359-65. PubMed ID: 2542526
[TBL] [Abstract][Full Text] [Related]
8. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological properties of a new non-steroidal anti-inflammatory drug: flunoxaprofen.
Lampa E; Romano AR; Berrino L; Tortora G; Di Guglielmo R; Filippelli A; Gentile B; Marmo E
Drugs Exp Clin Res; 1985; 11(8):501-9. PubMed ID: 2942383
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of a potent, new antithrombotic agent, 6-methyl-1,2,3,5-tetrahydroimidazo[2, 1-b] quinazolin-2-one hydrochloride monohydrate.
Fleming JS; Buyniski JP; Cavanagh RL; Bierwagen ME
J Pharmacol Exp Ther; 1975 Aug; 194(2):435-49. PubMed ID: 1151769
[TBL] [Abstract][Full Text] [Related]
11. Effect of a single Ditazole dose on platelet aggregation and prostaglandin formation.
Prisco D; Bartoletti A; Lombardi A
Int J Clin Pharmacol Res; 1984; 4(2):129-36. PubMed ID: 6147319
[TBL] [Abstract][Full Text] [Related]
12. Effects of droxicam on in vivo prostaglandin synthesis and ex vivo platelet aggregation.
Esteve J; Martínez L; Roser R; Sagarra R
Methods Find Exp Clin Pharmacol; 1987 Apr; 9(4):209-13. PubMed ID: 3110512
[TBL] [Abstract][Full Text] [Related]
13. The action of flupirtine on prostaglandin formation and platelet aggregation in vitro.
Darius H; Schrör K
Arzneimittelforschung; 1985; 35(1):55-9. PubMed ID: 3885962
[TBL] [Abstract][Full Text] [Related]
14. Preliminary double-blind evaluation of a new, non-steroidal anti-inflammatory drug: protacine.
Münzenberg J; Tachibana S
Pharmatherapeutica; 1980; 2(5):279-84. PubMed ID: 7001486
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition by fenflumizole tissue cyclooxygenase in rabbits ex vivo.
Basista M; Grodzińska L; Gryglewski RJ
Pol J Pharmacol Pharm; 1985; 37(1):41-6. PubMed ID: 3929239
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
17. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
18. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
[TBL] [Abstract][Full Text] [Related]
19. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
Cook NS; Bruttger O; Pally C; Hagenbach A
Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of proglumetacin and its metabolites after intravenous or oral administration in the dog.
Setnikar I; Arigoni R; Chisté R; Makovec F; Revel L
Arzneimittelforschung; 1987 Jun; 37(6):698-702. PubMed ID: 3663267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
